2 Information about fremanezumab

Marketing authorisation indication

2.1 Fremanezumab (Ajovy, Teva Pharmaceuticals) is indicated for 'prophylaxis of migraine in adults who have at least 4 migraine days per month'.

Dosage in the marketing authorisation

2.2 Fremanezumab is administered as a subcutaneous injection with 2 dosing options: 225 mg once a month or 675 mg every 3 months (quarterly). The treatment benefit should be assessed within 3 months after starting treatment. Any decision to continue treatment should be taken on an individual patient basis. Evaluating the need to continue treatment is recommended regularly afterwards.


2.3 The price of fremanezumab is £450.00 per 225-mg injection (£1,350 per 675 mg) excluding VAT; BNF online, accessed October 2019. The company has a commercial arrangement. This makes fremanezumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)